PIPELINE
DEVELOPMENT PIPELINE
Kala Is Advancing an Innovative Pipeline Based on its Proprietary Mesenchymal Stem Cell Secretome (MSC-S) Platform for the Treatment of Rare Front and Back of the Eye Diseases
| Product Candidate* | Indication | Route of Administration | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| KPI-012 for Rare Ocular Surface Disease | Persistent Corneal Epithelial Defect (PCED) (Phase 1) | Topical | ||||
| Ocular Manifestations of Moderate-to-Severe Sjögren’s (Preclinical) | Topical | |||||
| Partial Limbal Stem Cell Deficiency (LSCD) (Preclinical) | Topical | |||||
| KPI-014 Program for Rare Inherited Retinal Disease (Preclinical) | Intravitreal Injection |
*Product candidates are investigational and have not been approved by any regulatory authority.
